Company profile for BioNTech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioNTech SE is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all of the building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen ...
BioNTech SE is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all of the building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
An der Goldgrube 12 D-55131 Mainz
Telephone
Telephone
+49-6131-9084-0
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/18/3207494/0/en/BioNTech-Closes-Acquisition-of-CureVac-N-V-Including-Subsequent-Offering-Period-to-Strengthen-its-Unique-Position-in-the-mRNA-Field.html

GLOBENEWSWIRE
18 Dec 2025

https://www.biospace.com/fda/fda-plans-black-box-warning-for-covid-19-vaccines-report

BIOSPACE
12 Dec 2025

https://www.indianpharmapost.com/clinical-trials/biontech-and-bristol-myers-squibb-report-punchy-early-results-for-experimental-tnbc-therapy-18517

INDPHARMAPOST
11 Dec 2025

https://www.globenewswire.com/news-release/2025/12/09/3202233/0/en/BioNTech-and-Bristol-Myers-Squibb-Present-First-Global-Phase-2-Data-for-PD-L1xVEGF-A-Bispecific-Antibody-Pumitamig-Showing-Encouraging-Efficacy-in-Advanced-Triple-Negative-Breast-C.html

GLOBENEWSWIRE
09 Dec 2025

https://www.globenewswire.com/news-release/2025/12/06/3201090/0/en/BioNTech-and-OncoC4-Announce-Clinically-Meaningful-Overall-Survival-Benefit-for-Selective-Treg-Modulator-Gotistobart-in-Patients-with-Previously-Treated-Squamous-Non-Small-Cell-Lun.html

GLOBENEWSWIRE
06 Dec 2025

https://www.globenewswire.com/news-release/2025/12/03/3198964/0/en/BioNTech-Achieves-Minimum-Condition-in-CureVac-Exchange-Offer.html

GLOBENEWSWIRE
03 Dec 2025

Drugs in Development

read-more
read-more

Details:

BNT162b2 Vaccine is a vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.


Lead Product(s): BNT162b2 Vaccine

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Vaccine

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 24, 2025

blank

01

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : BNT162b2 Vaccine is a vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.

Product Name : Undisclosed

Product Type : Vaccine

Upfront Cash : Inapplicable

December 24, 2025

blank

Details:

PM8002 (Pumitamig) is a antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Glioblastoma.


Lead Product(s): Pumitamig,Bevacizumab,Temozolomide

Therapeutic Area: Oncology Brand Name: PM8002

Study Phase: Phase IIProduct Type: Antibody, Unconjugated

Sponsor: Bristol Myers Squibb

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 22, 2025

blank

02

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : PM8002 (Pumitamig) is a antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Glioblastoma.

Product Name : PM8002

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

December 22, 2025

blank

Details:

Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.


Lead Product(s): Pumitamig,Ipilimumab,Cabozantinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated

Recipient: Bristol Myers Squibb

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 19, 2025

blank

03

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

December 19, 2025

blank

Details:

Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.


Lead Product(s): Pumitamig,Ipilimumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated

Recipient: Bristol Myers Squibb

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2025

blank

04

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

December 18, 2025

blank

Details:

Through the acquisition of CV09050101, a vaccine targeting SARS-CoV-2 S, the deal aims to advance research in glioblastoma.


Lead Product(s): CV09050101

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Vaccine

Recipient: CureVac

Deal Size: $1,250.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition December 18, 2025

blank

05

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : Through the acquisition of CV09050101, a vaccine targeting SARS-CoV-2 S, the deal aims to advance research in glioblastoma.

Product Name : Undisclosed

Product Type : Vaccine

Upfront Cash : Undisclosed

December 18, 2025

blank

Details:

Pumitamig is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.


Lead Product(s): Pumitamig,Oxaliplatin,Paclitaxel,Gemcitabine

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibody, Unconjugated

Sponsor: Bristol Myers Squibb

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 01, 2025

blank

06

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : Pumitamig is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

December 01, 2025

blank

Details:

BNT162b2 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.


Lead Product(s): BNT162b2

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Vaccine

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 29, 2025

blank

07

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : BNT162b2 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.

Product Name : Undisclosed

Product Type : Vaccine

Upfront Cash : Inapplicable

October 29, 2025

blank

Details:

Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Stomach Neoplasms.


Lead Product(s): Pumitamig,Fluorouracil,Calcium Folinate,Oxaliplatin,Nivolumab,Capecitabine

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated

Recipient: Bristol Myers Squibb

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 27, 2025

blank

08

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Stomach Neoplasms.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

October 27, 2025

blank

Details:

Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Colorectal Neoplasms.


Lead Product(s): Pumitamig,Fluorouracil,Calcium Folinate,Oxaliplatin,Cetuximab,Capecitabine

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated

Recipient: Bristol Myers Squibb

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 27, 2025

blank

09

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Colorectal Neoplasms.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

October 27, 2025

blank

Details:

BNT329 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.


Lead Product(s): BNT329

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Antibody-drug Conjugate

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 22, 2025

blank

10

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

BioNTech

Germany
arrow
BIO Partnering at JPM
Not Confirmed

Details : BNT329 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

September 22, 2025

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty